Post by stevil on Jan 9, 2016 1:58:12 GMT -5
This is all well and good, but why don't people spend their efforts researching companies like MNKD that went bankrupt to draw parallels? Y'all wonder why you were blind to what happened yet you only allow yourself to see half the story...
Open both eyes, then make your judgement...
www.biospace.com/news_subject_all_results.aspx?CatagoryId=40096
It is quite depressing reading through it, but it does not really validate the notion that MNKD's demise is a done deal. The overwhelming majority of bankruptcies occurred for developmental companies that did not have an FDA approved product. The four that I did find are Dendreon and Affymax in 2014, Savient in 2013, and Oscient in 2009. Affymax is a special case because a post-approval safety issue was discovered with its product, leading to a subsequent revocation of FDA approval. I found no instance in which the dissolution of a partnership agreement was listed as a factor, so you can make a case that if Sanofi's snub leads to MNKD becoming bankrupt, then it will be a unique instance.
Another data point that should be considered is the number of Al Mann founded companies that have gone bankrupt. The answer to that is zero as far as I can tell. The truth of the matter is that MNKD should already be bankrupt, and Afrezza not exist as an approved drug, based on this data and the fact that Afrezza experienced two FDA rejections. That this did not happen speaks to Al's old-school ethics and general stubbornness, which I am counting on, but which also seems to often be overlooked.
In the court of law, a jury can't issue a verdict without hearing both the defense and prosecution. I'm just arguing for a fair trial. At some point, the prosecution needs to show up on this board.